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ABSTRACT 
According to the UNAIDS global report 2013, an estimated 6.1 million people are living with 
human immunodeficiency virus (HIV) in South Africa.  The incidence of Kaposi sarcoma (KS) 
has increased dramatically since the Acquired Immunodeficiency Syndrome (AIDS) 
epidemic.  Of the estimated 66 200 cases of KS worldwide, 58 800 are thought to have 
occurred in SSA (Parkin 2002).  However, there remains a paucity of published data about 
KS from South Africa.  This retrospective study was conducted to describe the epidemiology 
of KS at Chris Hani Baragwanath Academic Hospital (CHBAH) and to determine possible 
links among the CD4 counts, intensity and distribution of human herpes virus 8 latency- 
associated nuclear antigen 1 (HHV8 LNA-1) immunohistochemical staining and the stage of 
KS. 
Nine hundred and thirty eight histopathology reports of KS diagnosed in 901 patients at 
CHBAH between 2005 and 2009 were reviewed and demographic data (age, gender, 
topographic site, CD4 count, HIV status, KS stage, HHV8 LNA-1 staining, concomitant 
pathology) were recorded.  The H&E stained sections and HHV8 LNA-1 immunostains of a 
cohort of 127 cases were subsequently reviewed and categorised with regard to intensity 
and distribution of staining.  
The male:female ratio was 1,2:1.  The mean age was 36,8 years (standard deviation {SD} 
10,2 years) and the median CD4 count 127,5 cells/mm3 (quartile range {QR} 184,5 
cells/mm3).  Lower limb skin biopsies accounted for 49,6% of cases.  Concomitant pathology 
was seen in 4,6% of cases.  Infections and inflammatory dermatoses were the most 
frequently diagnosed concomitant pathology in cutaneous biopsies.  Paediatric, visceral and 
endemic KS accounted for only limited proportions of cases (1,44% of patients; 1,4% and 
1,3% respectively).  There was a significant difference in the distribution of HHV8 LNA-1 
staining in patch versus nodular KS (p = 0,011).  The CD4 counts were not predictive of KS 
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stage (p = 0,701) or the intensity (p = 0,877) and distribution (p = 0,846) of HHV8 LNA-1 
immunohistochemical staining.  
This study highlights the epidemiology of KS and the variability in HHV8 LNA-1 
immunohistochemical staining across CD4 counts and stages of KS. 
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Chapter 1: INTRODUCTION 
1.1. Background 
Kaposi sarcoma (KS) is a disease that was first described by Moritz Kaposi in 1872.  Four 
forms have since been described - classic KS, African/endemic KS, acquired 
immunodeficiency syndrome (AIDS) related KS and transplant related KS.  Although 
regarded as a neoplasm, KS in many regards is not a typical cancer.  It is usually multifocal, 
may regress with immune restoration and the cells are dependent on exogenous growth 
signals in vitro (Ganem 2006).  KS is characterised by violaceous patches, plaques or 
nodules most commonly in mucocutaneous sites.  However, lymph nodes; visceral organs 
and unusual sites such as bone may also be involved (Radu & Pantanowitz 2013).  
Diagnosis is made on histological examination of submitted biopsies and may be confirmed 
with relevant ancillary investigations eg. human herpes virus 8 latency associated nuclear 
antigen 1 (HHV8 LNA-1) immunohistochemistry (IHC). 
According to the UNAIDS global report 2012; 23,5 million people are living with the human 
immunodeficiency virus (HIV) in sub-Saharan Africa (SSA).  Of the estimated 66 200 cases 
of KS worldwide, 58 800 are thought to have occurred in SSA (Parkin 2002).  The disease 
burden in SSA is therefore enormous.  The majority of KS cases seen in SA are AIDS 
related. 
   
1.2. Problem statement 
AIDS related KS is a diagnosis made on a daily basis at the Chris Hani Baragwanath 
Academic Hospital (CHBAH) histopathology laboratory, yet published data from this hospital 
are lacking.  There are minimal data from SA regarding the frequency of cutaneous versus 
extracutaneous KS, the mean age at diagnosis of KS, the gender ratio, the most common 
stage of lesions at biopsy diagnosis, the mean CD4 count at time of biopsy, the prevalence 
of paediatric KS, the prevalence of endemic KS and the prevalence of dual pathology i.e. the 
finding of an additional pathological process in addition to KS in the same biopsy.   
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1.3. Rationale   
The purpose of this study is to address some of the abovementioned deficiencies in the 
literature as it pertains to patients at CHBAH, the largest hospital in the Southern 
Hemisphere.   
In addition to highlighting the epidemiology of KS at CHBAH, the variability of HHV8 LNA-1 
immunohistochemical staining will also be addressed.  The diagnosis of KS is made 
histopathologically by examination of routine haematoxylin and eosin stained sections and 
confirmed by IHC for HHV8 LNA-1.  Interestingly, the HHV8 LNA-1 immunoreactivity pattern 
may be variable in intensity and distribution.  There is limited literature addressing this 
variability of HHV8 LNA-1 immunohistochemical staining and the potential association with 
the patient‟s CD4 count.  Are the different patterns of staining possibly related to the CD4 
count of the patient at time of biopsy?  Is staining more diffuse in nodular stage KS when 
very low CD4 counts are present and less so with earlier lesions when high CD4 counts are 
present?  In the South African context, where the vast majority of cases of KS are AIDS 
associated, the relationship of HHV8 LNA-1 staining to the CD4 counts and various stages 
of KS would be interesting to determine.  In contrast to the limited number of AIDS 
associated KS cases used by researchers (Hong et al 2003; Patel et al 2004; Pak et al 2005; 
Ramos da Silva et al 2007), this study will incorporate a greater number of cases due to the 
high prevalence of AIDS associated KS in the sample population group.  
 
1.4. Specific aims and objectives 
 Aims of the study 
1. To describe the epidemiology of KS at CHBAH from 2005 to 2009.  
2. To describe the variability of HHV8 LNA-1 staining across the three stages of KS and 
CD4 counts in a retrospective cohort of patients. 
 
 Objectives 
a. To determine the male-to-female (M:F) ratio of KS  
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b. To determine the mean age at diagnosis of KS  
c. To determine the median CD4 count at time of diagnosis of KS  
d. To determine the frequency of KS at various topographic sites including the 
frequency of visceral KS  
e. To determine the prevalence of KS in the paediatric age group  
f. To determine the prevalence of endemic KS  
g. To determine the frequency of the patch, plaque and nodular stages of KS at the time 
of histological diagnosis  
h. To determine if the CD4 count is predictive of the stage of KS  
i. To determine the prevalence of special histomorphological variants 
j. To determine the prevalence of concomitant pathology in KS biopsies  
k. To determine if there is relationship between the CD4 count and the distribution 
and/intensity of HHV8 LNA-1 immunohistochemical staining.  
l. To determine if there is a relationship between the stage of KS and the distribution 
and/intensity of HHV8 LNA-1 immunohistochemical staining.  
 
1.5. Significance 
CHBAH provides health care services to a population that bears the brunt of HIV infection 
and KS.  The findings of this research project may highlight the vast extent of KS for 
allocation of much needed resources.  Documentation of the various demographic aspects 
of the disease will be of historical, clinical and pathologic interest as the long term effects of 
highly active antiretroviral therapy (HAART) begin to emerge.  
The literature review that follows will highlight available data from Africa and more recent 
developments in KS research that have emerged from abroad.  
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Chapter 2: LITERATURE REVIEW 
The literature review contains background literature on the clinical classification, 
epidemiology, risk factors, pathology and treatment of KS.  
 
2.1. Clinical classification 
Four distinct types of KS are recognised.  These include the classic, African/endemic, 
iatrogenic/transplant associated and HIV associated/epidemic types.   
The classic type KS occurs typically in elderly Mediterranean males.  The African/endemic 
type occurs in young African males and was first described in 1914.  The lymphadenopathic 
variant of endemic KS affects young children.  The iatrogenic type is seen in patients on long 
term immunosuppressants and in recipients of organ transplants.  In 1981, epidemic KS was 
first described in homosexual males who were HIV positive (Ruocco et al 2013).   
 
2.2. Epidemiology 
The majority of cases of KS seen in SSA are AIDS-associated.  HIV infection is associated 
with a 50 fold increased risk of developing KS (Mosam et al 2010).  
 
2.2.1. M :F ratio 
KS is considered to have a gender bias, being commoner in men since its appearance in 
homosexual males in the United States of America (USA) (Aboulafia 2000).  There are 
several hypotheses for this gender bias.  Some investigators believe that androgens may 
play a role (Christeff et al 1995).  However, Ziegler et al (1995) confirmed that KS lesional 
cells lack sex hormone receptors.   
The “iron hypothesis” suggests that the lower incidence of endemic KS in females may be 
due to their lower iron reserves than men as iron is needed for the development of KS 
(Simonart 2004). 
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A study by Ramos da Silva et al (2007) which included 25 cases of AIDS associated KS 
from Brazil, demonstrated a M: F ratio of 24:1.  Although the sample size was limited, this is 
in stark contrast to the African experience.  
In Africa, KS was found to be the most common neoplasm in adult Ugandan men (Orem et 
al 2004).   
Sitas & Newton (2000) demonstrated a male to female ratio of 2:1.  This gender ratio 
reflected an increase in incidence in women from 7:1 in 1988.  Data from the National 
Cancer Registry between1992-1996 was used in the abovementioned study.   
Pitche et al (2007) described a M:F ratio of 1,4:1 in cases of HIV KS compared to a ratio of 
9:1 in cases of African KS.  Mosam et al (2008) showed a M:F ratio of 1:1 and furthermore 
demonstrated that women presented earlier, with more disseminated disease and had a 
poorer prognosis compared to men.  
 
2.2.2. Age 
A Nigerian study revealed a mean age of 36,3 years (Onunu et al 2007).   
Mosam et al (2008), in a study of 152 patients with HIV associated KS, demonstrated that 
the mean age in males was 37 years (range 25-64 years) and in females 34 years (range 
19-64 years).  
In a subsequent publication, Mosam et al (2009) highlighted that KS now occurs at a much 
younger age.  The mean age of patients with KS decreased from 59,7 years in 1983 (pre-
AIDS era) to 36,5 years in 2006.   
 
2.2.3. Paediatric KS 
Ziegler & Katongole-Mbidde (1996) described KS in childhood in their analysis of 100 cases 
from Uganda.  The mean age reported was 4 years.  The commonest topographic region of 
involvement was the head and neck and the M:F ratio was 1:1,7.  
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Amir et al (2001) compared paediatric KS before and during the AIDS epidemic in Tanzania.  
Boys were more commonly affected than girls especially in the 0-5 year age group with a 
ratio of M:F of 11:1.  Twelve per cent of cases seen in the AIDS era involved sites not 
usually involved in the pre-AIDS era.  These sites included genitalia, eyelid, ear, lip and face.  
There was also an increase in upper limb involvement in contrast to decreased numbers of 
lower limb and lymph node cases.  
In 2010, Gantt et al, described KS in 73 patients who were younger than 18 years of age.  
Included in their study were mostly clinically diagnosed cases with only 36% (n=26) being 
biopsy confirmed KS cases.  Although 40% of cases showed lymph node involvement, the 
reliability of this data is questionable as some of these cases were not histologically 
confirmed and the causes of lymphadenopathy in HIV positive patients are myriad.  The 
mean age recorded was 10,1 years of age and the M:F ratio; 1,03:1.   
Similarly, Cox et al (2013) described 81 cases of paediatric KS in Malawi and Botswana with 
biopsy diagnosis in only 25% of cases.  The lack of pathology expertise was cited as the 
reason for the failure to obtain histological confirmation.  
Tukei et al (2011), in a large retrospective study of HIV associated malignancies in children 
presenting at the Baylor-Uganda Paediatric HIV Clinic in Kampala; Uganda, recorded 97 
cases of KS in 6530 patients between the ages of 6 weeks to 18 years.  Seventy six of these 
cases were in children ≤12 years of age.  Thirty two per cent had lymph node involvement, 
26% had cutaneous lesions and 5% had visceral KS.  
There have been two recent publications of paediatric KS from SA.  In a series of 9 cases of 
KS in children diagnosed between January 2003 and December 2007, Cairncross et al 
(2009) documented oropharyngeal and inguino-scrotal involvement most commonly.  Three 
cases involved the gastrointestinal tract (GIT).  The study revealed that the incidence of 
paediatric KS had increased to 2 patients per year from 1 child every 4 years before the HIV 
epidemic at Red Cross Children‟s Hospital, Cape Town, South Africa.  The sample size was, 
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however, limited.  In a recent study, Stefan et al (2011) described 70 cases of HIV 
associated paediatric KS from patients between 0 and 14 years which were diagnosed at 3 
large hospitals in SA.  A M:F ratio of 1,59:1 and a median age of 72 months were 
highlighted.  Skin involvement was seen in the majority of cases (57,14%); nodal 
involvement in 30,15% and visceral involvement in 38,09% of cases.  The mean CD4 count 
was 440 cells/mm3.  This data obtained from the South African Children‟s Cancer Registry 
confirmed a substantial increase in paediatric KS from only one case reported in 1998 to 26 
cases reported in 2008. 
 
2.2.4. Topographic sites of involvement 
KS occurs in the skin, oral mucosa, lymph nodes, lungs, GIT, genitalia, oropharynx, tonsils, 
nasal cavity, liver, spleen and less commonly bone marrow. 
Mucocutaneous KS is most common (Radu & Pantanowitz 2013) with lower limbs being 
most commonly affected (Onunu et al 2007). 
In literature cited by Bunn et al (2013), the oral cavity may represent the initial site of KS in 
up to 22% of cases and is usually the first sign of HIV infection.  Involvement of buccal 
mucosa can be seen in up to 50% of cases of AIDS associated KS (Pitche et al 2007).   
In an autopsy study by Leimlich et al (1987) involving 24 patients with HIV associated KS, 
29% of patients showed visceral involvement in the absence of skin lesions.  The most 
common viscera involved were lung (37%) and those of the GIT (50%).  Nodal KS was seen 
in 50% of cases.  
GIT involvement may be found in 40% of cases at initial diagnosis and in up to 80% of 
patients at autopsy (Dezube 1996).  The stomach is most frequently involved followed by the 
oesophagus, colon and small bowel (Slavik 2012). 
Miller et al (1992) showed an 8% prevalence of bronchopulmonary Kaposi sarcoma in their 
study involving 361 HIV positive patients who underwent bronchoscopy.  Mitchell et al (1992) 
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in a similar study found 19 patients with bronchopulmonary KS in the 140 patients who 
presented for bronchoscopy.  Interestingly, all 19 patients also had cutaneous lesions.  
Unusual sites of involvement have also been reported in the literature.  These include brain, 
peripheral nerves, spinal cord, heart, eye, ear, pancreas, breast, wounds, blood clots, 
thoracic duct and heart.  Involvement of these unusual sites has not been widely 
documented except for random reports which formed the basis of the review article by 
Pantanowitz & Dezube (2008).  As KS is thought to derive from endothelium, the rare 
occurrence of KS in the brain and eye is thought to be to due secondary spread of KS from 
other sites (Rahman & Mazumber 2002).   
 
2.3. Risk factors 
The risk of developing Kaposi sarcoma is related to human herpes virus 8 (HHV8) 
seropositivity.  HHV8 is also known as Kaposi sarcoma–associated herpesvirus (KSHV).  
Viral DNA is always found in KS lesions (using PCR) and HHV8 infection rates are high in 
groups in which KS is frequent (Ganem 2006).  
Whitby & Howard (1995) described that HIV positive patients with HHV8 in their peripheral 
blood are more likely to have KS and detection of HHV8 in HIV positive patients without KS 
predicts progression to KS.  In an interesting study, Rezza et al (1999) demonstrated that 10 
years after HIV seroconversion, 30% of HHV8 positive individuals developed KS and that the 
risk of KS increased with increasing anti-HHV8 antibody titres.   
HIV predisposes to KS by infecting and depleting CD4 expressing T lymphocytes which are 
responsible for the helper function of the immune response.  This in turn impairs defense 
against HHV8.  The CD4 count is widely regarded as a specific marker for immunodeficiency 
(Clifford & Fransceschi 2009).  
Portsmouth et al (2003) suggested that nadir CD4 cell counts were an independent factor 
associated with KS development.  Similarly, Biggar et al (2007) agreed that the incidence of 
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KS was strongly associated with declining CD4 counts.  In contrast to these findings, it has 
recently been highlighted that severe immunosuppression is not required for the 
development of KS.   
The minimum CD4 count recorded by Mosam et al (2008) in their study was 1 cell/mm3 and 
the maximum 1406 cells/mm3.  Thirty eight per cent of patients had CD4 counts of >200 
cells/mm3 and 21% had CD4 counts more than 350 cells/mm3.  Similarly, Cassol et al (2005) 
demonstrated that 50% of KS patients in their cohort had CD4 counts >150 cells/mm3 and 
38,5% had CD4 counts >400 cells/mm3.  More recently, Mani et al (2009) and Crum-
Cianflone et al (2010) confirmed that KS occurs in HIV positive patients with undetectable 
viral loads and CD4 counts of >300 cells/mm3 and >350 cells/mm3 respectively.  This trend 
has also been observed in HAART naïve patients (Daly et al 2014) and is strong motivation 
for the initiation of HAART at higher CD4 counts than previously.  
De Souza et al (2007) confirmed that latency associated nuclear antigen (LNA) antibody 
detection in serum by immunoflourescence assay (IFA) correlated with CD4 counts of 
patients with KS.  When CD4 counts increased, previously seronegative patients became 
seropositive when follow-up IFA-LNA was performed.  Therefore, studies involving LNA 
detection by IFA should include patients with CD4 counts of more than 300 cells/mm3.   
 
2.4. Pathology 
2.4.1. Cell of origin 
The cell of origin of KS is controversial.  However, many researchers favour an endothelial 
origin (Horenstein et al 2008).  As early as 1985, Beckstead et al convincingly demonstrated 
resemblance of KS cells to lymphatic endothelium using immunohistochemical and lectin 
histochemical procedures with markers like Ulex europaeus 1 lectin and 5´-nucleotidase.  
The lymphatic origin of these endothelial cells has also subsequently been supported by 
positive D-240 immunohistochemical expression (Rosado et al 2012).  Using oligonucleotide 
microarrays, Wang et al (2004), postulated two possible theories 1: that HHV8 infects both 
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lymphatic and blood endothelial cells and drives gene expression profiles of each type closer 
to that of the other and 2: that HHV8 infects endothelial cell precursors in vivo and drives 
these cells toward a lymphatic endothelium genotype.  
Therefore, the downstream effect of HHV8 infection results in reprogramming of host‟s 
endothelial cells and subsequent resemblance to lymphatic endothelium.  Lymphatic vessel 
endothelium receptor 1, and vascular endothelial growth factor 3 are also all upregulated in 
KS lesions (Radu & Pantonowitz 2013). 
 
2.4.2. HHV8/KSHV 
HHV8 is a gamma herpes virus with a long latency period.  The virus was first identified by 
Chang et al (1994) using representational difference analysis to identify DNA sequences 
uniquely present in KS tissue compared to non diseased tissue obtained from the same 
patient.  Since their pioneering work, other independent researchers have confirmed that 
HHV8 is associated with all forms of KS.  
Boshoff et al (1995) used polymerase chain reaction (PCR) to demonstrate that HHV8 was 
present in spindle cells and endothelial cells of KS lesions.  Similarly, Smith et al (1997) 
identified HHV8 DNA in 8 of 9 KS biopsies using PCR and furthermore demonstrated higher 
immunofluorescence antibody titres against HHV8-lytic and latent antigens in the sera of 
their KS positive cohort compared to those patients without KS.  Kennedy et al (1998) 
subsequently used PCR in 16 cases of early KS and detected HHV8 in 87% of cases.  They 
also confirmed that HHV8 amplicons were localised to endothelial and spindle cell 
proliferations.  
Bezold et al (2001) described no significant differences in HHV8 DNA copies in paraffin 
embedded biopsies from HIV negative versus HIV positive KS cases.  Quantitation of copy 
numbers was done by competitive PCR.  The HIV negative cases used were of the classic 
type.  This research group used 14 biopsies from only 4 HIV negative patients in the study 
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whereas the HIV positive cases originated from 13 separate patients.  CD4 counts and the 
stage of the lesions were not considered.  The study implied that CD4 count and other 
factors related to HIV may not impact on the quantity of HHV8 DNA in KS lesions.  
The seroprevalence of HHV8 is high (83%) in patients with KS (Sitas et al 1999).  
HHV8 is also associated with primary effusion lymphoma, Castleman disease and large B-
cell lymphoma arising in the setting of HHV8 associated multicentric Castleman disease.  In 
vitro studies with HHV8 have been performed with primary effusion lymphoma cell lines.  
Only a handful of endothelial based models for HHV8 study are available as spindle cells 
cultured from KS do not maintain the HHV8 genome (Moses et al 2002).  This is a limiting 
factor in all forms of research relating to HHV8 and the pathogenesis of KS.  Consequently, 
there remain many unanswered questions regarding the pathogenesis of KS.   
 
 Prevalence 
There is geographic variation in the prevalence of HHV8 seropositivity with more than 50% 
seropositivity in SSA, 20-30% seropositivity in Mediterranean countries and less than 10% in 
Europe, Asia and USA (Uldrick & Whitby 2011).  Gao et al (1996) showed that HHV8 
seroprevalence is higher in Ugandans compared to Americans and Italians.  
Two studies published in 1999 based in SA revealed an HHV8 seroprevalence of 32% and 
34,5% respectively (Wilkinson et al, Sitas et al).  The prevalence of HHV8 antibodies 
increased with increasing age, increased number of sexual partners and decreased with 
increasing levels of education.  In addition, HHV8 serum antibodies were more prevalent in 
Black patients compared to White patients (Sitas et al 1999).  
Maskew et al (2011) confirmed an HHV8 seroprevalence of 48% in their study based in a 
Johannesburg clinic involving 440 HIV positive patients.  The KSHV positive group was 
found to have a higher body mass index (>18,5kg/m2) and higher CD4 counts.  
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 Mode of transmission 
Modes of transmission of HHV8/KSHV include sexual transmission among homosexual 
males, oral exposure to infectious saliva, vertical transmission and blood transfusion 
(Wilkinson et al 1999).  
HHV8 has been detected in the saliva of 75% of HIV infected patients.  The presence of 
HHV8 in saliva may be due to its affinity to localise in B lymphocytes in tonsillar tissue 
(Koelle et al 1997).   
HHV8 can also be transmitted sexually.  In support of this, the virus has been found, to 
varying degrees, in the genital tract of HIV positive women (Calabro et al 1999; Whitby et al 
1999) and in the semen of 8% of HIV infected males (Pellet et al 1999).  A 35% 
seroprevalence was observed in bisexual and homosexual HIV positive males (Kedes et al 
1996).  The practice of oral-genital and receptive anal intercourse may account for the high 
transmission rates of HHV8 in homosexual men (Dukers et al 2000; Melbye et al 1998).   
In a large study from Carltonville, Malope et al (2008) argued that there is no evidence that 
KSHV is sexually transmitted.  Their results showed an overall prevalence of KSHV of 
47,5%.  Although the prevalence of HHV8 in the peripheral blood was higher in sex workers, 
this was not significantly different from other groups in their study.  The prevalence of KSHV 
did not follow the pattern of sexually transmitted infections (STIs).  Sexual intercourse and 
the number of sexual partners were not risk factors.  The prevalence of KSHV was found to 
be similar in HIV negative and HIV positive groups and in individuals with and without STIs.  
As the HHV8 virus is detectable in peripheral blood, transmission via blood and blood 
products is possible (Whitby et al 1995).  
The possibility of transmission via intravenous drug use has not been not clearly established.  
Vertical transmission especially in HIV positive mothers is an important potential mode of 
transmission especially in SA where the rate of vertical transmission of HIV is also high.  
Bourbolia et al (1998) highlighted that approximately one third of HHV8 positive mothers 
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infect their children.  Other investigators have disputed vertical transmission of HHV8 
arguing that children born to HHV8 positive mothers have passively transmitted antibodies 
and sero-revert by age 2 years (Calabro et al 2000).  
  
 Replication 
HHV8 has both lytic and latent phases of replication.  In situ hybridisation studies have 
shown that most spindle cells in KS are latently infected.  Only 1-3% of cells show lytic 
replication.   
Four major proteins are involved in latency, LNA; viral cyclin D (vCYC D); viral FLICE-
inhibitory protein (vFLIP) and Kaposin B.  Lytic genes include K1, vIL-6, viral interferon 
regulatory factors, viral Bcl-2, viral macrophage inflammatory proteins and four interferon 
regulatory factors (Horenstein et al 2008). 
 
2.4.3. Pathogenesis of KS 
Douglas et al (2007) suggested that the pathogenesis of Kaposi sarcoma is complex and 
involves 4 main steps including initiation, proliferation, inflammation and tumourigenesis.  
Initiation involves infection of endothelial cells with KSHV.  These cells then home and 
proliferate in response to anti-apoptotic genes and pro-angiogenic molecules.  The 
inflammation component involves secretion of cytokines and finally there is activation of 
autocrine and paracrine signalling with subsequent spindle cell proliferation to produce the 
lesions of KS.  
HHV8 is necessary for KS development (Dittmer & Krown 2007).   
 
 HHV8 Latent genes 
HHV8 latent genes, LNA; vCYC D; v-FLIP and Kaposin are able to deregulate cellular 
growth.  LNA will be discussed due to its application in IHC.  
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LNA is consistently expressed in KS across all stages.  Open reading frame (ORF) 73 
encodes LNA which mediates episome persistence.  LNA interacts with p53 resulting in 
resistance to p53 mediated apoptosis (Komatsu et al 2001).  This in turn promotes cell 
survival.  LNA binds to the tumour suppressor, retinoblastoma, resulting in loss of 
retinoblastoma function.  LNA also acts directly on host-gene expression.  Cells that express 
LNA, dysregulate host genes such that when LNA is fused to GAL4, it inhibits expression of 
GAL4-dependant reporters.  
Once endothelial cells are latently infected, they undergo a conformational change to 
resemble spindle cells (Ganem 2006).  This accounts for the presence of spindle cells in KS 
lesions.   
 
 HHV8 Lytic genes 
HHV8 lytic genes eg. Kl and v-MIP-1 provide strong paracrine signals to adjacent latently 
infected cells (Horenstein et al 2008).  
 
 C-kit 
The role of c-kit in KS has been demonstrated by Moses et al (2002) by showing enhanced 
expression of c-kit.  Indirect evidence has been CD117 immunohistochemical expression in 
these tumours and response to anti-c-kit therapy (Gleevec).  C-kit is a proto-oncogene that is 
induced by HHV8.  C-Kit activation increases the response of tumour cells to growth factors 
and thereby accelerates cell proliferation and conformational changes (Kandemir et al 
2009a). 
 
 PDGFR 
Platelet derived growth factor receptor (PDGFR) is upregulated but not mutated in KS 
(Dittmer & Krown 2007).  PDGFR induces angiogenesis through vascular endothelial growth 
factor (VEGF) (Koon et al 2005).  The process of angiogenesis to increase blood supply is 
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thought to be a response to injury, further in support of the theory that KS is an inflammatory 
lesion (Douglas et al 2007).  
HHV8 infection alone is not sufficient to cause KS as not all HHV8 positive patients will 
develop KS (Miles et al 1996).  Other factors such as HIV infection, decreased immunity due 
to other causes, as well as inflammatory cells and iron are also thought to play a role.  
 
 HIV and host immunity 
HIV is a co-factor in AIDS related KS.  This is supported by a decrease in the incidence of 
KS with reduction in HIV viraemia and regression of KS lesions with HAART treatment.  The 
mechanisms by which HIV promotes the development of KS are unclear.  Some researchers 
propose that HIV tat protein is a growth factor for KS.  HIV infection upregulates cytokines 
which then promote spindle cell survival and growth.  HIV may induce T cell depletion and 
immunosuppression thereby facilitating KS progression (Ganem et al 2006).  Patients with 
HIV are at increased risk for all cancers that have an infectious aetiology (Grulich et al 2007) 
as HIV lowers the immune response to infectious agents like HHV8 (Clifford & Francheschi 
2009). 
Dysregulation of host immunity is thought to be important in the pathogenesis of KS as the 
disease manifests in immunosuppressed patients ie. HIV positive patients and transplant 
recipients.  It is thought that in these individuals, HHV8 infected spindle cells escape immune 
surveillance and are able to progress to KS.  The risk of developing KS is linked to both 
cellular and humoral immunity.  It has been verified that both decreasing CD4 and CD19 
counts are associated with an increased risk for developing KS (Stebbing et al 2004; Biggar 
et al 2007).   
 
 Inflammatory cells 
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Inflammatory cells are observed in most KS lesions.  They are sparse in early lesions and 
are well established in the tumour stage.  The inflammatory cells comprise plasma cells, 
lymphocytes and dendritic cells.  Constant signalling from KS lesional tissue acts as a 
stimulus for infiltration by inflammatory cells.  These inflammatory cells in turn, secrete 
cytokines, chemokines and other growth factors that stimulate growth and progression of KS 
lesions (Pantanowitz et al 2009a).  There is hyperactivation of the humoral response (Th2-
mediated) and a decrease in the cellular response (Th1-mediated) (Douglas et al 2007). 
 
 Iron and KS 
Haemosiderin is an integral component of all KS lesions.  Using in vitro studies, Simonart et 
al (1998) demonstrated that iron may be a co-factor in KS development for the following 
reasons: addition of iron salts stimulated growth of KS cells and addition of iron chelators 
reduced cell growth, iron decreased host defenses by inhibiting CD4 lymphocytes and 
macrophages and iron loading was found to enhance production of HHV8 viral nucleic acids.   
The high incidence of endemic KS in places like Uganda and Sudan may be explained by 
the absorption of iron through bare feet from soil in iron oxide rich volcanic clays (Simonart 
2004).  
Aluminosilicates may also be absorbed by walking bare feet.  These cause obstruction of 
lower limb lymphatics resulting in lymphoedema and chronic lymphostasis which result in 
local immunodeficiency and predispose to opportunistic infections and tumours (Ruocco et al 
1984; Ruocco et al 2013). 
 
 Other factors 
Use of nitrite inhalants among homosexual men with AIDS has also been linked to KS, as 
have quinine (and analogues) and ACE inhibitors.  The link to quinine is supported by the 
high prevalence of KS in malaria areas that use quinine and is thought to be due to the 
drugs‟ well known immunosuppressive effects (Ruocco et al 2013).   
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2.4.4. Histopathogical features 
Histopathologically, Kaposi sarcoma is a vasoformative lesion comprising a proliferation of 
spindle cells with formation of slit-like vascular spaces.  Extravasated red blood cells, 
haemosiderin, hyaline globules and plasma cells are also usually present.  Hyaline globules 
are derived from fragmented erythrocytes (Radu & Pantanowitz 2013).   
Three stages are morphologically recognised, patch; plaque and tumour/nodular.  Patch 
stage KS is the earliest phase of KS and may be subtle and easily missed.  It is 
characterised by a vasoformative process centred around native blood vessels.  Slit-like 
vascular spaces may also be seen dissecting the dermal collagen.  The promontory sign is 
characterised by protrusion of newly formed blood vessels into an existing vessel.  Plaque 
stage lesions demonstrate a more diffuse cellular proliferation.  The cells are more spindled 
and may be arranged in fascicles.  Nodular KS lesions are typified by a circumscribed 
proliferation of spindle cells arranged in fascicles.   
Several special morphologic variants have been comprehensively described by Grayson & 
Pantanowitz (2008).  Anaplastic KS is locally aggressive, displays a significant degree of 
nuclear pleomorphism, is more mitotically active and may show necrosis.  
Lymphoedematous variants include lymphangioma-like (lymphangiomatous) KS, 
lymphangiectatic KS and bullous KS.  The lymphangioma-like variant may show two 
patterns.  The first comprises a conventional patch or plaque stage KS with irregular, ectatic 
vessels dissecting dermal collagen.  The second pattern shows larger vessels in the 
superficial dermis mimicking lymphangioma circumscriptum.  The lymphangiectatic variant 
has large, dilated vessels and the bullous variant (usually a clinical diagnosis), comprises a 
subepidermal or intraepidermal bullous.  The telangiectatic variant of KS shows large, 
congested ectatic vascular spaces with features of nodular KS.  Hyperkeratotic or verrucous 
KS shows verrucous acanthosis and hyperkeratosis overlying a typical KS lesion.  Keloidal 
KS shows the spindle cell proliferation of KS amongst thick, glassy collagen.  Micronodular 
KS comprises a small nodule of KS in the mid to deep dermis.  Pyogenic granuloma-like KS 
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comprises superficial nodular KS that has undergone ulceration and mimics a classic 
pyogenic granuloma.  In ecchymotic KS, there is marked red cell extravasation.  
Intravascular KS shows a spindle cell proliferation within the lumen of a vessel.  
Biopsy of regressing lesions may show subtle features including an increase in dermal 
capillaries, perivascular plasma cells, stromal sclerosis, haemosiderin laden macrophages 
and spindle cells around native vessels (Grayson & Pantanowitz 2008).  
Occasionally, concomitant pathology may be identified during light microscopic examination 
of biopsy specimens with KS.  Concomitant pathology may include cryptococcosis, 
cytomegalovirus or granulomatous inflammation (Radu & Pantanowitz 2013).  Grayson 
(2011) estimated that a combination of lesions is encountered in less than 2% of biopsies 
from HIV positive patients.  In his comprehensive review, he cites cases of KS in 
combination with infections, non infective dermatoses and dual neoplasia in the same 
biopsy.  Cryptococcus, Histoplasma, Candida, Molluscum contagiosum, Mycobacterium 
Avium Intracellulare, Mycobacterium tuberculosis and Cytomegalovirus have all been 
recorded in combination with KS.  Interface dermatitis (inflammation at the dermo-epidermal 
junction) may occasionally be seen as part of “AIDS interface dermatitis”, due to a drug or 
with no identifiable underlying aetiology.  KS of the penis with concomitant squamous cell 
carcinoma in situ of the surface epithelium has also been recorded.   
Classic KS with sarcoid like granulomas has also been described and is thought to be a 
reaction to the tumour and tumour antigens akin to the granulomatous response 
documented in carcinomas (Kandemir et al 2009b).  Fifteen biopsies of concomitant KS and 
Mycobacterium tuberculosis-associated granulomatous inflammation were described by 
Ramdial et al 2010.  Investigation of concomitant granulomatous inflammation required 
special stains to detect an infective organism and molecular studies.  Confirmation of 
Mycobacterium tuberculosis infection may serve as a clue to undiagnosed HIV infection, 
systemic tuberculosis, non compliance to treatment or multidrug resistance.  Inflammatory 
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oncotaxis and Koebner phenomenon have been proposed as mechanisms for co-lesional 
KS and tuberculosis.   
Bunn et al (2013) documented concomitant pathology in 25 of 135 cases of oral KS.  The 
majority of cases showed superficially invasive candidiasis in addition to KS.  This is not 
surprising as HIV positive patients frequently have oral candidiasis due to 
immunosuppression.  One case showed Cytomegalovirus and another showed necrotising 
granulomatous inflammation.  
KS has been noted in 13% of patients with unicentric Castleman disease and 75% of 
patients with multicentric Castleman disease (Bowne et al 1999).  Oksenhendler et al (1996) 
reported on KS and multicentric Castleman disease in 20 HIV positive patients.  KS was 
present 5 – 54 months before the diagnosis of Castleman disease in 6 patients and 
developed simultaneously in an additional 6 patients.  Histological examination of the 20 
lymph node biopsies revealed subtle KS lesions co-existing with Castleman disease in as 
many as 8 cases.  The plasmablastic variant is most commonly seen in the setting of HIV 
infection and is characterised by plasmablasts in the mantle zone (Stebbing et al 2008).  
HHV8 LNA-1 IHC highlights positively staining cells in the mantle zone (Dupin et al 1999).  
 
2.4.5. Diagnosis:  
The diagnosis of KS is based on the clinical context (eg. presence of immunosuppression) 
recognising the clinical features (eg. violaceous mucocutaneous lesions) coupled with the 
abovementioned morphological and relevant immunophenotypic characteristics.   
 
 Clinical features 
Patients may present with minimal or disseminated disease (Douglas et al 2007).  Clinically, 
early skin and mucosal lesions may be difficult to recognise as they appear as faint, red 
brown to violet macules.  Usually, they present as violaceous papules, plaques or nodules.  
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There may be associated lymphoedema (Dezube 1996).  Punch biopsies of skin are often 
taken to confirm the diagnosis.  
Patients with bronchopulmonary KS usually present with respiratory symptoms such as 
cough and breathlessness with synchronous skin lesions (Mitchell et al 1992).  Chest X ray 
and bronchoscopy can reveal lymphadenopathy, pleural effusion, peripheral nodules, 
endobronchial lesions or an interstitial infiltrate (Aboulafia 2000).  
Patients with GIT KS may present with abdominal pain, nausea, weight loss, gastrointestinal 
bleeding, intestinal obstruction or diarrhoea.  Endoscopy may reveal macules with 
submucosal haemorrhage or nodules.  There may be a low diagnostic yield of biopsy due to 
possible submucosal or deeper locations of KS.  As such, deeper biopsies may need to be 
performed in suspected cases of GIT KS (Friedman et al 1985). 
There are several clinical staging schemes for KS.  Mitsuyasu divided KS into 4 stages with 
stage I being localised nodular KS in elderly men in North America and Europe and stage IV 
representing disseminated KS with visceral involvement.  A 4 tier staging system originally 
proposed by Schwartz in 1984 has since been modified to include the presence of 
opportunistic infections, HIV seropositivity and cutaneous anergy into categories A, B and C 
respectively (Schwartz et al 2008).  
The AIDS Clinical Trials Group (ACTG) classification devised in 1988, classifies the tumour 
extent, immune system status (as determined by CD4 count) and systemic illness as good 
risk or poor risk.  Nasti et al (2003) recommended that this staging needs revision in the 
HAART era as the CD4 count does not seem to provide prognostic information. 
  
 Immunohistochemistry 
HHV8 can be detected by IHC, PCR and in situ hybridisation.   
IHC is a readily available and timeous means of confirmation of KS.  IHC is performed on 
formalin fixed paraffin embedded tissue using commercially available monoclonal antibodies 
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to different viral antigens.  Monoclonal antibodies to KSHV LNA-1 are available.  LNA-1 
helps viral DNA attach to host chromosomes, therefore immunoreactivity appears as nuclear 
stippling.  Lytic replication is only seen in a small percentage of cells, therefore it cannot be 
utilised in IHC (Pantanowitz et al 2009b).  Application of HHV8 LNA-1 IHC may be required 
in cases where the morphological appearance mimics other vasoformative lesions such as 
pyogenic granuloma and angiosarcoma.  HHV8 LNA-1 IHC is also diagnostically useful in 
subtle patch stage KS and when KS occurs in unusual topographic regions (Pantanowitz et 
al 2009b). 
HHV8 IHC using LNA-1 anti-HHV8 antibody is sensitive (95%) and specific (100%) (Robin et 
al 2004).  Hammock et al (2005) similarly found that 92% of KS lesions were positive with 
HHV8 LNA-1 IHC whilst none of the haemangiomas or epithelioid haemangioendotheliomas 
included in their study showed staining.   
Of their 37 cases of KS, Hong et al (2003) detected HHV8 LNA-1 immunopositivity in 80% of 
patch, 88% of plaque and 74% of nodular KS.  Interestingly, they asserted that HHV8 LNA-1 
immunohistochemical staining was unrelated to age, gender, tumour recurrence, multiplicity 
or site of the lesions.  Ramos da Silva et al (2007) applied HHV8 LNA-1 IHC to 64 cases, 41 
(64%) of which revealed positive staining.  Their sample included AIDS-KS (n = 25), 
classical KS (n = 20), iatrogenic KS (n = 2) and KS NOS (n = 17).  Positive staining in the 
AIDS KS cases were seen in all nodular KS (which represented only 4 cases), in 6 of 9 
patch and 7 of 8 plaque stage KS.  The authors did not state their criteria for positive 
staining. 
Positive immunohistochemical staining with HHV8 LNA-1 may show varying intensity and 
distribution.  Some cases reveal only focal staining with isolated punctate staining in 
occasional nuclei whilst other cases stain diffusely within all lesional nuclei.  Although 
Pantanowitz et al (2009b) has cautioned against comparing staining across the stages due 
to the greater number of cells in nodular KS compared to patch/plaque stage, there are 
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earlier studies that have assessed staining across the different stages.  Patel et al (2004) 
and Pak et al (2005) demonstrated that more cells stained with HHV8 LNA-1 in nodular 
stage compared to patch/plaque stage KS.  In early patch stage KS, only 10-30% of spindle 
cells may express latent genes whilst in later lesions, almost all cells express latent genes 
(Dupin et al 1999).  A possible explanation proposed for this variability is that early lesions 
are thought to be hyperplastic and proliferative whilst the more advanced lesions of nodular 
and plaque stage are clonal (Miles 1996, Rabkin et al 1997).   
Robin et al (2004) also alluded to the variability in staining and furthermore noted that the 
different epidemiologic forms of KS showed no specific variations.   
Patel et al (2004) assessed HHV8 LNA-1 staining in 21 cases of KS.  Stage was applied to 
13 cases of cutaneous KS.  Three were nodular and 10 were patch/plaque.  This group of 
investigators defined positive staining as strong and diffuse staining in >10% of cells.  Three 
cases of nodular KS showed positivity in ≥40% of cells.  In their cases of patch/plaque KS, 1 
showed positivity in 10%, 4 in 20% and the remaining 5 in ≥40% of cells.  Interestingly, they 
regarded focal and weak staining in less than 10% of cells as negative.  Other studies have 
regarded any nuclear staining as positive, with no quantitative criteria specified (Hong et al 
2003). 
CD31 and CD34 IHC may be also be used to confirm the diagnosis of KS.  FLi1 and D-240 
have also shown to be of use and are positive in 100% of AIDS related KS (Rosado et al 
2012).  Pantanowitz et al (2005) reported CD117 (C-kit) immunoreactivity in 43% of their 
cohort of classic, AIDS related and endemic KS cases.  This CD117 positivity has been cited 
as a potential pitfall in the diagnosis of KS and gastrointestinal stromal tumours which are 
also CD117 and CD34 positive (Rossi et al 2009). 
 
 Other ancillary tests 
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PCR is performed when IHC is negative, yet the suspicion for KS is high.  PCR is subject to 
false positives as circulating lymphocytes may harbour HHV8.   
KSHV in situ hybridisation may also be used to detect the virus in Kaposi sarcoma lesions 
(Horenstein et al 2008). 
  
2.5. Management  
Despite the huge burden of disease in resource limited settings, application of simple 
treatment options is possible and effective.  
According to Lorenzo et al (2007), treatment options for AIDS related KS include 
antiretroviral therapy, local treatment (radiation; topical agents), cytotoxic chemotherapy and 
targeted agents.  
KS lesions regress with initiation of HAART.  HAART inhibits HIV replication, decreases 
production of HIV-tat and ameliorates the immune response to HHV8 (Cattelan et al 2002).  
Semeere et al (2012) reviewed literature to assess the impact of HAART on the incidence of 
KS in resource rich and resource limited settings.  Data was cited from the Southern Africa 
International Epidemiologic Databases to evaluate AIDS (IeDEA) as showing an incidence of 
624 per 100 000 person years among non-HAART users and 174 per 100 000 person years 
in HAART users, equating to a reduction of 72%.  The most effective treatment modality 
remains HAART. 
Besides side effects, HAART may be associated with immune reconstitution syndrome 
(IRIS).  IRIS is an inflammatory reaction that occurs after initiation of HAART.  It is due to 
reconstitution of the immune system which is now able to recognise pathogens that were 
previously asymptomatic.  IRIS is associated with an increase in CD4 count and a decrease 
in HIV viral load.  Progressive or recrudescent KS lesions may occur as part of IRIS 
(Ramdial 2010).  Patients with IRIS-KS have a higher CD4 count and more tumour-
associated oedema (Bower et al 2005). 
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Chemotherapy which includes anthracyclines is used for treatment of visceral disease and 
progressive mucocutaneous lesions.  Local therapy such as radiotherapy is useful for 
palliation, for management of bulky lesions and for cosmesis.  In this era of molecular 
medicine, targeted pathogenesis based treatments such as anti-angiogenic compounds, 
retinoic acid, hormonal agents and anti-herpes agents are also being used in the treatment 
of KS.  Tyrosine kinase inhibitors eg. imatinib have been shown to induce regression as 
PDGF, PDGFR and c-kit play a role in KS pathogenesis (Lorenzo et al 2007).  
Developed countries have shown a 24 month survival rate of 58% in patients living with 
AIDS and diagnosed with KS (Biggar et al 2005).  But, in resource limited settings, such as 
SSA, weak infrastructure is a limiting factor in conducting clinical trials.  Poverty, late 
diagnosis, lack of cancer treatment centres and trained professionals in combination with 
inconsistent availability of treating agents are barriers to rendering optimal care to patients 
(Krown 2011).  Of the estimated 6.1 million people living with HIV in South Africa, only          
2 010 340 adults are reported to be on HAART (UNAIDS global report 2013).  
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Chapter 3: METHODS 
3.1. Study design 
An observational retrospective cross sectional study design was used. 
 
3.2. Target population and sampling technique 
3.2.1. Target population: 
The target population included all cases of KS diagnosed at the Histopathology Laboratory, 
Division of Anatomical Pathology, National Health Laboratory Services (NHLS) at CHBAH, 
Soweto, Gauteng, South Africa from 1/1/2005 to 31/12/2009.  
 
3.2.2. Sampling technique: 
The sampling technique was purposive.  All cases diagnosed as KS, SNOMED code M-
91403, at the laboratory were included.  For the second component of the study, all cases of 
mucocutaneous KS with available CD4 counts and HHV8 LNA-1 immunohistochemical 
stains were included in the sample.  
 
3.2.3. Ethics 
An application for ethical approval of this study was submitted to the Wits Human Research 
Ethics committee.  Institutional ethics approval is important for all human studies.  Due to the 
retrospective nature of this research project, there was no contact with patients.   
The laboratory numbers were recorded and subsequently coded on a datasheet, thereby 
ensuring that patient anonymity was preserved.  Only linked-codes were used during 
statistical analysis.  Ethics approval was obtained (clearance no. M130533) from the Wits 
Ethics committee (see annexure 3).  Written permission to utilise the NHLS DISA system for 
the purposes of the study was obtained from the complex business manager (annexure 2).  
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3.3. Materials and data collection 
3.3.1. Data collection: 
The cases were retrieved using a SNOMED search of the DISA computer system at the 
NHLS laboratory at CHBAH.  Cases of KS diagnosed in the histopathology department 
during the above-stated time period were retrieved using the SNOMED code, M-91403 and 
the SNOMED search program.  Data were extracted from these laboratory reports and 
entered manually onto a datasheet (annexure 1).   
The following variables were recorded:  
 Age of the patient   
 Gender of the patient 
 HIV status (positive or negative) 
 CD4 count (included only if the patient had retroviral disease and recorded if tested 
within one month of the confirmatory biopsy) 
 Topographic region biopsied   
 Type of specimen submitted/biopsy method (punch, incisional or excisional) 
 Stage of KS (patch, plaque or nodular) 
 Concomitant pathology identified in the same biopsy specimen 
The information entered was cross checked on three occasions and subsequently 
transposed onto an Excel spreadsheet.  Data for most of the variables except for CD4 count 
and HIV status were obtained from the histology reports.  HIV status and CD4 counts were 
extracted in most cases from relevant serological investigations and CD4 reports available 
on the DISA laboratory system.   
Cases of paediatric KS were extrapolated from the main dataset.  For the purposes of the 
study “paediatric” was defined as children less than 14 years of age as per admission 
regulation at CHBAH.  Nodal KS cases were reviewed.  
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The second component of the study involved selecting all mucocutaneous KS cases where 
CD4 counts and HHV8 LNA-1 immunohistochemical stains were available.  The original 
haematoxylin and eosin stained slides and HHV8 LNA-1 immunohistochemically stained 
slides were retrieved from the histopathology archives.  All cases with previously performed 
HHV8 LNA-1 IHC and available CD4 counts were reviewed by a single pathologist (the 
researcher) and entered onto a separate Excel data spreadsheet.   
The distribution (either focal or diffuse) and intensity (either weak or strong) of HHV8 LNA-1 
immunohistochemical staining were recorded on the datasheet together with the CD4 count 
of the patient and stage of KS (patch/plaque/tumour).  The histological stage was also 
assessed and recorded in those cases where it was not originally reported. 
The criteria for defining the histological stages were as those described by Grayson and 
Pantanowitz (2008).  Patch stage KS shows a subtle spindle cell proliferation mostly around 
native blood vessels.  Plaque stage KS comprises more spindle cells arranged in fascicles 
and tumour stage KS usually shows a nodular proliferation of tumour cells.  For the purposes 
of this study, focal staining has been defined as a limited proportion of lesional cells (i.e. 
≤10%) showing nuclear staining.  Diffuse staining has been defined as most (>10%) of 
lesional cells showing nuclear staining.  Weak staining has been defined as discrete, dot-like 
nuclear stippling.  Strong staining has been defined as complete nuclear staining (multiple 
closely packed dots).  Weak staining requires examination under high magnification (X400), 
whilst strong staining may be seen at low magnification (X100).  Positive staining is detected 
by a brown colour due to the chromogen used in IHC.  
Pantanowitz et al (2009b) have cautioned against comparing staining across the stages due 
to more lesional cells being present in nodular versus plaque versus patch stage.  In 
considering the distribution of HHV8 LNA-1 staining, the proportion of lesional cells that are 
positive were assessed rather than considering absolute number. 
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3.3.2. Reliability of data 
Demographic data entered onto the DISA system were obtained from the requisition slip 
completed by the submitting clinical doctor at the time of biopsy.  The reliability of data for 
this study is dependent on the accurate submission of information especially with regard to 
variables such as age, gender and biopsy topographic sites.  
The accuracy of data obtained from the DISA system is also reliant on data capturers who 
entered details from requisition slips.  
 
3.3.3. HHV8 LNA-1 immunohistochemistry  
All the reviewed HHV8 LNA-1 immunostains were performed in the histopathology laboratory 
at the Charlotte Maxeke Johannesburg Academic Hospital.  Where indicated, this stain was 
requested by the reporting pathologist at CHBAH.  
The staining was performed by a technologist/technician using the mouse monoclonal 
antibody against HHV8-LNA (dilution 1:100 from Novacastra).  Staining was done manually 
until the end of 2009, when an autostainer was acquired.  Slides were incubated overnight at 
37 degrees Celsius and then dewaxed in xylene for 10 minutes.  They were blocked with 
peroxidase for 10 min and the antibody was applied for 20min.  Chromogen was applied for 
10min and the slides were then counterstained with haematoxylin.  The slides were rinsed in 
buffer between all steps mentioned.  Microwave and high pH/EDTA were used in antigen 
retrieval.  Each test was run with the appropriate positive and negative controls as per 
quality assurance requirements and standards in the laboratory. 
 
3.4. Data analysis: 
All information collected was extrapolated onto an Excel spreadsheet.  
STATISTICA 12 was used for descriptive and analytic statistics.  Descriptive statistics have 
been performed as a total.  Continuous data (age, CD4 count) have been presented as 
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mean±SD if normal distributed and as median and quartile (QR) when the distribution was 
non-normal.  
Categorical data have been summarised as frequencies and percentages.   
The Mann-Whitney test was used when 2 independent variables (CD4 count and intensity of 
HHV8 LNA-1 staining, CD4 count and distribution of HHV8 LNA-1 staining) were compared 
and the Kruskell Wallace (median) test when multiple independent samples (CD4 count and 
nodular, patch, plaque stages) were compared.   
The Fisher exact test was used to assess if there were any significant differences in the 
staining intensity and distribution across the 3 stages. 
All data analysis was personally performed under the supervision of Prof Libhaber.  
The following chapter presents results obtained when the above methodology was applied.  
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Chapter 4: RESULTS 
A total of 901 patients with 938 biopsies were recorded.  The number of cases diagnosed 
per year is shown in Figure 1, below.   
 
 
 
Figure 1: Number of cases of KS histologically diagnosed in each year at  
CHBAH from 2005 and 2009. 
 
 
4.1. Male:Female ratio 
Of the total 901 patients that were biopsied, the gender was unknown/unspecified in one 
patient (n = 900).  A total of 488 males and 412 females were biopsied.  This equates to a 
male: female ratio of 1,18:1 for all cases of KS diagnosed.  
Of the 901 patients that were diagnosed with KS, 731 patients were confirmed as being HIV 
positive either in the clinical history provided by the submitting clinician or on a positive 
serological test located on the DISA computer system.  The gender was unknown in one 
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confirmed HIV positive patient (n = 730).  There were 396 males and 334 females (M:F = 
1,19:1). 
 
 
     
 
     Figure 2: Number of males versus number of females histologically diagnosed with  
     KS . 
 
 
4.2. Mean age at biopsy diagnosis 
The mean age at biopsy diagnosis of KS was 36,79 years (SD 10,24 years).  Age was not 
recorded in 12 patients (n = 889).  The youngest patient in this study was 1 year of age and 
the oldest patient 85 years.  
For the confirmed HIV positive subgroup of 731 patients, age was available in 726 patients. 
The mean age for this group was 36,43 years (SD 9,66 years) and median 35,50 years (QR 
12,00 years) . 
The mean age for confirmed HIV positive males was 38,08 years (SD 9,32 years) and the 
median 37,00 years (QR 11,00 years).  The mean age for confirmed HIV positive females 
was 34,46 years (SD 9,72 years) and the median 33,00 years (QR 12,00 years). 
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Figure 3: Distribution of age at time of biopsy for all patients diagnosed with KS. 
 
 
4.3. CD4 count at KS biopsy diagnosis 
The mean CD4 count within one month of first biopsy diagnosis was 155,74 cells/mm3 (SD 
143,58 cells/mm3) and the median CD4 count was 127,50 cells/mm3 (QR 184,50 cells/mm3).   
The CD4 counts were unknown in 361 patients (n = 540).  382 patients had CD4 counts less 
than 200 cells/mm3, 127 CD4 counts between 200 cells/mm3 and 400 cells/mm3 and 27 
patients had CD4 counts between 400 cells/mm3 and 600 cells/mm3  
For the confirmed HIV positive group, CD4 counts were available for 536 patients.  The 
median CD4 count was 126,00 cells/mm3 (QR 184,50 cells/mm3) and the mean 155,29 
cells/mm3 (SD 143,24 cells/mm3).  
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The confirmed HIV positive males had a median CD4 count of 130,00 cells/mm3 (QR 127,67 
cells/mm3) and the confirmed HIV positive females had a median CD4 count of 120,50 
cells/mm3 (QR 181,00 cells/mm3). 
 
 
 
                           
Figure 4: Distribution of CD4 count at time of biopsy. 
 
 
   Table 1: CD4 counts of confirmed HIV positive patients, males and females  
   diagnosed with KS and all cases diagnosed with KS.  
 
  *The gender was unknown in one patient 
         n Median   Quartile range 
CD4 count females 236 120,50 cells/mm3 181,00 cells/mm3 
CD4 count males 299 130,00 cells/mm3 182,00 cells/mm3 
CD4 total (HIV confirmed) 536* 126,00 cells/mm3 184,50 cells/mm3 
CD4 count of all cases  540 127,50 cells/mm3 184,50 cells/mm3 
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4.4. Topographic sites 
Topographic sites were recorded in 674 biopsies and were unspecified in 264 biopsies.  Of 
the total 674 where topographic sites were specified; 81,45% of the biopsies were from skin; 
6,97% of biopsies were from the oral cavity and 4,0% were from lymph nodes.  Most skin 
biopsies (334/551) were from the lower limbs. 
The one case recorded in the breast was reviewed and showed spindle cells infiltrating 
among terminal duct lobular units.  HHV8 IHC performed on this case was positive. 
Table 2 (overleaf) shows the specific topographic sites involved. 
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Table 2: Distribution of topographic sites involved by KS. 
Visceral  n 
 Oesophagus 1 
 Stomach 6 
 Small bowel 2 
 Colon 1 
 Anus 1 
 Lung 2 
                  Total 13 
Oral cavity  
 Tonsil 5 
 Tongue 8 
 Palate 23 
 Oral cavity not otherwise specified 4 
 Gingiva 3 
 Alveolar  1 
 Lip 3 
                 Total 47 
Lymph node 27 
Skin  
 Abdomen/trunk/back 17 
 Lower limbs 334 
 Upper limbs 125 
 Head and neck 27 
 Chest/breast  40 
 Genital area 6 
                  Total 549 
Eye  
 Eyelid 18 
 Conjunctiva 9 
 Eye not otherwise specified 3 
                  Total 30 
Pharynx/larynx 7 
Breast  1 
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4.5. Visceral KS 
Thirteen cases of visceral KS were identified.  
The organs involved are shown in the pie graph (figure 5) below.  Most of the biopsies of 
visceral KS were from the stomach. 
 
 
 
*Data is presented as absolute numbers 
 
Figure 5: Distribution of visceral organs involved by KS.  
 
 
4.6. HIV status 
The HIV status was unknown in 161 cases.  Seven hundred and thirty one patients (98,78%) 
were HIV positive and 9 were HIV negative confirmed on HIV enzyme-linked immunosorbent 
assay (HIV-ELISA) (n = 740).   
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    Figure 6: Number of HIV positive and HIV negative patients diagnosed with KS. 
 
 
4.7. HHV8 LNA-1  immunohistochemical staining 
HHV8 LNA-1 immunohistochemical staining was performed in 289 biopsies.  There were 
271 (94%) positive results and 18 (6%) negative results.  
Twelve biopsies from 9 HIV negative patients were recorded.  Nine HHV8 LNA-1 
immunohistochemical stains were performed on the total 12 HIV negative KS biopsies.  One 
(11%) of the total nine HHV8 LNA-1 immunohistochemical stains performed on the biopsies 
from the HIV negative patients, was negative.  The remaining 10 were positive.  
 
 
4.8. Paediatric KS 
Thirteen (1,44%) cases of paediatric KS (diagnosed in patients younger than 14 years) were 
identified.   
Seven male children and 6 female (M: F= 1,17: 1) were noted.   
The mean age was 6,46 years (SD 3,36 years) and the median 7,00 years (QR 4,00 years). 
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Of the 13 cases, HIV status was unknown in two patients, was negative in 1 and positive in 
10 patients.  
Six CD4 counts were available, with a mean of 209,15 cells/mm3 (SD 141,85 cells/mm3) and 
a median of 217,0 cells/mm3 (QR 204,0 cells/mm3).   
The topographic sites for the paediatric cases are shown in figure 7 below.  The one child 
who was HIV negative had an incisional skin biopsy from the arm.  The diagnosis of KS was 
confirmed with a positive HHV8 immunohistochemical stain.  
 
 
*Data is presented as absolute numbers 
 
Figure 7: Topographic sites involved by KS in children younger than 14 years. 
 
 
4.9. Endemic KS 
Twelve biopsies of KS from 9 confirmed HIV negative patients were seen.  There was no 
history of transplantation in these patients.  No further clinical history of immunosuppression 
was provided.  Five HIV negative patients were males, whilst 4 were females (M:F = 1,25: 
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1).  The mean age was 55,44 years (SD 19,72 years).  The topographic sites involved are 
shown below (figure 8).  
 
 
 
    *Data is presented as absolute numbers 
 
Figure 8: Topographic sites of endemic KS. 
 
 
 
All nine patients with endemic KS had serological investigations for HIV performed, see table 
3 below.   
 
Table 3: HIV testing performed on the patients with endemic KS 
Patient A HIV ELISA x 1 negative 
Patient B HIV ELISA x 1 negative 
Patient C HIV ELISA x 1 negative 
Patient D HIV ELISA x 5 negative 
Patient E HIV ELISA x 1 negative 
Patient F HIV ELISA x 2 negative 
Patient G HIV ELISA x 2 negative 
Patient H HIV ELISA x 2 negative 
Patient I HIV ELISA x 1 negative 
6
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1
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Upper limb
Breast
Buttock
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4.10. Stage of KS at biopsy diagnosis  
Stages of Kaposi sarcoma ie. patch, plaque or nodular were recorded in the histopathology 
reports of 708 biopsies and were not recorded in 230 biopsies.   
109 cases were of patch stage, 380 cases were of plaque stage and 219 cases showed 
nodular stage KS.   
 
 
 
Figure 9: Stages of KS at diagnosis. 
 
 
Figure 10 overleaf shows the differences in histomorphology among patch, plaque and 
tumour/nodular stage KS. 
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        Figure 10: A Patch stage KS, B Plaque stage KS & 
                   C Tumour stage KS (X100 magnification). 
A B 
C 
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Figure 11: Patch stage KS, “busy dermis” (X200 magnification). 
 
 
 
 
 
   Figure 12: HHV8 LNA-1 immunohistochemical staining in subtle patch  
  stage KS (X200 magnification), same case as figure 10 (A) above. 
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Figure 13: Plaque stage KS (X200 magnification). 
 
 
 
         Figure 14: Tumour stage Kaposi sarcoma with 
        ulceration of overlying mucosa (X100 magnification). 
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4.11. Relationship of median CD4 count to stages of KS 
No statistically significant correlation was demonstrated between the median CD4 count and 
the stage of KS (p = 0,701). 
 
 
Table 4: Relationship of CD4 count to stage. 
 
 
4.12. Morphological variants of KS 
Classic histopathological features of KS are a spindle cell proliferation, formation of slit-like 
vascular spaces, extravasated red blood cells, haemosiderin pigment, hyaline globules and 
plasma cells as shown in the figures (15-23) below.   
 
 
 
Figure 15: Fascicles of spindle cells with red cell extravasation. 
 
Stage (n) 
 
Nodular (31) 
 
Patch (40) 
 
Plaque (56) 
 
P value 
 
CD4 count 
(median, IQR) 
 
146,0 cells/mm3 
(193 cells/mm3) 
 
168,5 cells/mm3 
(230,5 cells/mm3) 
 
129,0 cells/mm3 
(169,5 cells/mm3) 
 
      
0,701 
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Figure 16: Spindle cell proliferation with extravasated red blood cells. 
 
 
 
  Figure 17: Slit like vascular spaces (black arrow) and haemosiderin pigment  
  (white arrow). 
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Figure 18: Conspicious plasma cells (white arrow). 
 
 
 
Figure 19: Hyaline globules. 
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 Figure 20: Haemosiderin pigment. 
 
 
 
 
Figure 21: Plasma cells (white arrow), extravasated red blood cells (black arrow) and       
spindled cells (blue arrow). 
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Figure 22: Hyaline globules (white arrow) and extravasated red blood cells  
(black arrow). 
 
 
 
Figure 23: Promontory sign. 
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Special morphological variants were recorded in 17 cases.  All 17 of these patients were HIV 
positive.  Lymphangioma-like/lymphangiomatous, lymphangiectatic and telangiectatic 
variants were documented as shown in table 5 below.  The lower limb biopsies accounted 
for the most of the cases diagnosed with a special morphological variant. 
 
 
          Table 5: Morphological variants of KS and topographic sites of these biopsies. 
 
Site  
 
Morphological variant 
 
 
 
Lymphangioma 
like 
 
Lymphangiectatic 
 
Telangiectatic 
 
Total for 
specific site 
Lower limbs 4* 3 0 7 
Upper limbs 3 1 0 4 
Eyelid/conjunctiva 1 0 0 1 
Oropharynx 1 0 0 1 
Unknown 2 1 1 4 
Total for specific 
variant 
11 5 1  
*Data is presented as absolute numbers 
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  Figure 24: Lymphangiectatic variant (arrows indicate dilated lymphatics). 
 
 
 
 
Figure 25: Lymphangiomatous variant of KS (X200 magnification). 
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4.13. Concomitant pathology 
Concomitant pathology was noted in 43 (4,6%) of 938 biopsies.  Infections, inflammatory 
dermatitis and panniculitis were most commonly documented as dual pathology in 
cutaneous KS biopsies as shown in table 6 overleaf.  
Seven cases of granulomatous inflammation and KS were seen in the same biopsy.  Five 
were recorded in skin punch biopsies, 1 was from a lymph node and an additional case was 
from the breast.  Ziehl-Neelsen and Periodic Acid Schiff special stains performed on all 7 
cases were negative for micro-organisms.  PCR for Mycobacterium genus was performed on 
1 case of cutaneous KS with granulomatous inflammation and was positive.  Acid fast bacilli 
were detected in the sputum of another patient with cutaneous KS and granulomatous 
inflammation.  
 
 
 
 
Figure 26: Granulomatous inflammation and KS (X200 magnification). 
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Table 6: Concomitant pathology in biopsies in which KS was diagnosed. 
 
 
The 3 cases of concomitant candidiasis were recorded in oral cavity biopsies.  
There were 27 cases of nodal KS, 12 of which showed concomitant pathology.  One showed 
granulomatous inflammation (noted above), 10 showed HIV lymphadenitis/Castleman 
disease-like features and 1 showed concomitant Castleman disease.  There were 2 cases 
diagnosed as showing Castleman disease-like features.  These were stained with HHV8 
Type of concomitant pathology n 
Infections  
 Cytomegalovirus 3 
 Candida 3 
 Cryptococcus 1 
 Possible Syphilis 2 
 Herpes 1 
Subtotal 10 
Dermatitis  
 Seborrheic dermatitis 1 
 Spongiotic dermatitis 1 
 Interface dermatitis 4 
 Granulomatous inflammation 7 
Subtotal 13 
Panniculitis 4 
Other  
 Papilloma 1 
 Verruca 1 
 Chalazion 1 
 Intussusception 1 
 Gastritis 1 
 HIV lymphadenitis/Castleman disease 
like 
10 
 Castleman disease 1 
Total 43 
Page | 53  
 
LNA-1 and the histology although diagnostic for KS fell short of the criteria for true 
Castleman disease.  These two cases were reviewed by multiple pathologists at the time of 
sign out.  The eight cases showing HIV lymphadenitis demonstrated follicle-lysis, expansive 
or atrophic germinal centres and interfollicular plasma cells.  The features in two skin punch 
biopsies raised the possibility of concomitant syphilis due to the dense lymphoplasmacytic 
infiltrate.  In one case, Warthin Starry special stain was performed and was negative. 
Confirmatory serological investigations for syphilis were advised by the reporting 
pathologist/s.  However, no records of syphilis serological investigations were subsequently 
found. 
 
 
 A total of 132 cases were initially selected for review of HHV8 LNA-1 immunohistochemical 
staining.  Only 127 cases could be reviewed.  The slides could not be located in 4 cases and 
one of the cases had a poor section with extensive folding of the tissue rendering it un-
interpretable.  Of the total 127 cases reviewed, there were 40 (31,5%) patch stage, 56 
(44,09%) plaque and 31 (24,41%) nodular stage cases. 
 
 
4.14. Distribution of HHV8 LNA-1 immunohistochemical staining across the stages 
of KS 
Of the total 127 biopsies reviewed, 110 showed diffuse (>10% of lesional cells showing 
nuclear staining) and 17 showed focal (≤10% of lesional cells showing nuclear staining) 
HHV8 LNA-1 immunohistochemical staining.   
The distribution of HHV8 LNA-1 staining across each of the stages, patch; plaque and 
nodular are shown in table 7 below.  Most cases that stained diffusely were plaque stage 
and only one case of nodular KS showed focal staining.   
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Table 7: Distribution of HHV8 LNA-1 staining, number of cases that showed diffuse and 
focal staining in each of the 3 stages. 
*Data is presented as frequencies and percentages 
 
 
No statistically significant differences were noted as a total but when individual stages were 
compared, a statistically significant difference was noted in the distribution of staining 
between patch and nodular stage KS (p = 0,011 = <0,016).  No significant differences were 
calculated for patch vs plaque (p = 0,06) or plaque vs nodular stages (p = 0,21).  
 
 
Stage  
 
      
Distribution 
 
 
 
 
Diffuse 
 
Focal 
 
Patch 
 
30 (27,3%) 
 
10 (58,8%) 
 
 
Plaque 
 
50 (45,5%) 
 
 
6 (35,3%) 
 
Nodular 
 
30 (27,3%) 
 
 
1 (5,9%) 
 
Total  
 
110 (100%) 
 
 
17 (100%) 
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Figure 27: A & B: Strong and diffuse HHV8 LNA-1 immunohistochemical  
staining (X100 magnification). 
A 
B 
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Figure 28: A & B: Weak HHV8 LNA-1 immunohistochemical staining, X400  
magnification indicated by arrows. 
A 
B 
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  Figure 29: Strong HHV8 LNA-1 immunohistochemical staining indicated by  
              brown nuclear staining (X400 magnification). 
 
 
4.15. Intensity of HHV8 LNA-1 immunohistochemical staining across the stages of 
KS 
Of the 127 biopsies reviewed, 102 showed strong staining (complete nuclear staining with 
multiple closely packed dots seen at low magnification) with HHV8 LNA-1 
immunohistochemical stain and 25 showed weak staining (discrete, dot-like nuclear stippling 
that can only be seen at high magnification).   
Table 8 overleaf shows the intensity of staining across the three stages.  Only 3 cases of 
nodular KS showed weak staining.   
No statistically significant difference was noted in the intensity of staining across the 3 
stages of KS (p = 0,30).  When the intensity of combined patch and plaque stage were 
compared against nodular stage there was no statistical significance (p = 0,08).   
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Table 8: Intensity of HHV8 LNA-1 staining, number of cases that showed strong and weak 
staining in each of the stages. 
*Data is presented as frequencies and percentages 
 
 
Figure 30 below allows for comparison of HHV8 LNA-1 immunohistochemical staining. 
 
 
Figure 30:  Number of biopsies showing weak/strong and focal/diffuse HHV8 LNA-1 
immunohistochemical staining across the three stages of KS. 
 
0
5
10
15
20
25
30
35
40
45
50
Patch Plaque nodular
N
u
m
b
e
r 
o
f 
b
io
p
si
e
s
Stage of KS
Weak
Strong
Focal
Diffuse
 
Stage 
 
 
Intensity 
 
 
 
 
Strong 
 
Weak 
 
Patch 
 
 
30 (29,4%) 
 
10 (40%) 
 
Plaque 
 
 
44 (43,1%) 
 
12 (50%) 
 
Nodular 
 
 
28 (27,5%) 
 
3 (12%) 
 
Total 
 
 
102 (100%) 
 
25 (100%) 
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4.16. Relationship of CD4 count to intensity and distribution of HHV8 LNA- 
immunohistochemical staining 
The study showed that CD4 count was not predictive of the intensity or distribution of HHV8 
immunohistochemical staining (p value = 0,878 and 0,846 respectively). 
 
 
Table 9: Relationship of intensity (weak/strong) and distribution (focal/diffuse) of HHV8 LNA-
1 immunohistochemical staining to CD4 count  
 
  
Intensity (n) 
 
Weak (25)  
 
 
Strong (102) 
 
P value 
 
Median CD4count (IQR) 
 
 
121 (221) 
 
148 (191) 
 
0,878 
 
Distribution (n) 
 
Focal (17) 
 
 
Diffuse (110) 
 
P value 
 
Median CD4count (IQR) 
 
 
121 (199) 
 
147 (194) 
 
0,846 
 
 
CD4 counts were log transformed and the distribution was not normal.  Using the same 
statistical tests to compare, there was no statistically significant difference found for stage, 
distribution and intensity of HHV8 LNA-1 staining. 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
Page | 60  
 
Chapter 5: DISCUSSION 
Of the tens of thousands of cases of KS diagnosed worldwide, the vast majority are thought 
to have occurred in SSA (Parkin 2002).  Much has changed since HIV associated KS was 
first recognized in homosexual males in the 1980‟s.  The pathogenesis of KS has been 
extensively investigated and HHV8 has been linked to KS.  While developed countries are 
experiencing a decline in the incidence of KS due to timeous HAART initiation, in developing 
countries, like South Africa, KS remains a cause of significant morbidity and mortality due to 
lack of optimal availability of HAART (Semeere et al 2012).   
SSA is home to approximately 80% of the world‟s HIV-infected female population and 
heterosexual transmission of HIV remains the main mode of spread worldwide (De Cock et 
al 2012).  In SSA, women younger than 20 years of age are eight times more likely to be HIV 
infected compared to males in the same age range (Abdool Karim 2013).  The UNAIDS 
global report 2013, estimated that approximately 13,9% of females (vs 3,9% of males) 
between the ages 15 and 24 years were living with HIV in South Africa.  The male female 
ratio of patients diagnosed with confirmed HIV associated KS was 1,2:1 in this study, in 
keeping with the trend of KS shifting from a male predominant disease (Sitas & Newton 
2000) and is reflective of the high prevalence of HIV in young women who bear the brunt of 
HIV in South Africa.  This is in stark contrast to the initial recognition of KS as an 
overwhelmingly male predominant disease in homosexual men in the USA in the 1980‟s 
(Biggar & Rabkin 1996).   
Patients diagnosed with KS at CHBAH showed a mean age in males of 38 years and in 
females of 35 years.  This is similar to findings by Mosam et al (2008).  The mean age for all 
cases of confirmed HIV associated KS at CHBAH was 36 years; congruent with findings by 
Mosam et al (2009) of a mean of 36,5 years in 2006.  This is in contrast to the mean of 59,7 
years which was recorded (by Mosam et al) in cases from 1983 (pre-AIDS era).  The mean 
age of mid thirties may once again change as the long term effects of the antiretroviral roll-
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out programmes begin to emerge.  It is predicted that with HAART, HIV positive patients will 
live longer and thus may present later with KS (Daly et al 2014).  
Confirmed HIV positive males with KS at CHBAH during the study period had a mean CD4 
count of 157,40 cells/mm3.  A mean CD4 count of 153,22 cells/mm3 was demonstrated in the 
female patients.  The mean CD4 counts recorded were lower than that documented by other 
comparative studies.  Mosam et al (2008) demonstrated a mean CD4 count in males of 230 
cells/mm3 and a mean CD4 count in females of 205 cells/mm3.  The mean CD4 count for the 
entire cohort used by Mosam et al (2008) was 218 cells/mm3 compared to the CHBAH mean 
CD4 count recorded of 155,74 cells/mm3.  The mean CD4 count recorded by Onunu et al 
(2007) was 127 cells/mm3.  The wide range of CD4 counts recorded in the present study 
(minimum <1 cell/mm3 and maximum 1465 cells/mm3) is in keeping with the suggestion that 
in Africa severe immunosuppression is not a pre-requisite for the development of KS (Cassol 
et al 2005).  In fact, results of this study show that 158 patients at CHBAH diagnosed with 
KS (ie. 29,26% of the total 540 patients with known CD4 counts) had CD4 counts in excess 
of 200 cells/mm3.   
Mucocutaneous sites are most commonly involved in KS (Radu & Pantanowitz 2013).  Six 
hundred and thirty three (64,5%) biopsies of the total 938 received at the CHBAH 
Histopathology department originated from mucocutaneous sites.  Most of these biopsies 
were from the lower limbs (334 of 674 cases with recorded topographic sites).  Only 9 cases 
of visceral KS were found.  Ramos da Silva et al (2007) documented 6/64 (9,3%) cases of 
visceral KS.  However the specific viscera involved were unspecified.  Results of this study 
show that stomach and lung were most frequently involved followed by oesophagus, anus 
and small bowel.  This limited number may be attributed to under sampling as synchronous 
easily accessible mucocutaneous lesions in these patients may have been biopsied.  KS 
occurring in topographic sites considered unusual by Pantanowitz & Dezube (2008) that 
have been noted at CHBAH include larynx (2 cases), conjunctiva (9 cases) and breast (1 
case).   
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KS may be localised to the breast or may be part of more disseminated disease 
(Pantanowitz & Conolly 2002).  There have been only isolated reports of KS occurring in the 
breast (Hamed et al 2000, Michelow et al 2010).  This study contributes one additional case 
of KS which presented as a mass in the lower outer quadrant of the breast.  The patient was 
female, however the HIV status was not known.  Furthermore, there was no additional 
history regarding the presence of disseminated KS or KS confined exclusively to the breast 
parenchyma.  Four additional cases in the present study were of KS involving skin of the 
breast and one case derived from an intramammary lymph node presenting as a breast 
mass.   
Conjunctival and ocular adnexal KS have been reported by Schmid et al 2003 and Curtis & 
Durairaj 2005.  Nine cases of conjunctival KS (from 7 patients) were detected in this study.  
CHBAH laboratory provides histopathology service to the neighbouring St John‟s Eye 
Hospital thus accounting for the relatively high number of this topographic location being 
represented.   
Review of the clinical history in the reports showed that one of the two patients who was 
diagnosed with laryngeal KS at the CHBAH histopathology laboratory presented with 
complete airway obstruction.  Pantanowitz and Dezube (2008) cited 25 cases of laryngeal 
KS from the literature in their review with complete airway obstruction being one of the 
presenting signs.  No brain, spinal cord, heart, endocrine or urinary tract lesions were 
identified at CHBAH during the period of study.   
Results of our study show that the majority of patients (731 of 901; 81,13%) who were 
diagnosed with KS on biopsy were also confirmed to be HIV positive on serological testing.  
The HIV status was not available in 161 of 901 patients.  This may due to patients possibly 
refusing consent for retroviral testing.  Furthermore, an HIV test may have been performed 
at peripheral hospitals/clinics that are not linked to the DISA database at CHBAH and 
therefore these results could not be documented.  In some instances, clinicians may have 
failed to offer HIV testing to the patient at time of biopsy or failed to specify the patients‟ 
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status in the clinical history section of the requisition form.  KS is an AIDS-defining condition 
and clinical suspicion of the lesion should prompt verification of the HIV status.  Nine 
patients from our cohort were HIV negative.  Biopsies from these patients have been 
regarded as endemic KS.  No history of organ transplantation was specified in these 
patients.  In addition, the clinical files were not available for thorough review.  Unknown HIV 
test results in 161 cases are likely to underestimate the burden of true endemic/African KS 
seen at CHBAH.  
Ninety four percent of HHV8 LNA-1 immunohistochemical stains performed on KS biopsies 
at the CHBAH histopathology laboratory during the study period were positive, similar to 
findings by Hammock et al (2005) and in excess of the 78% positivity and 64% positivity 
recorded by Hong et al (2003) and Ramos da Silva et al (2007) respectively.  Interestingly, 
HHV8 LNA-1 staining was only applied in 289 of the 938 (30,8%) of biopsies at CHBAH 
during the study period.  This is reflective of variable individual pathologists‟ practice as in 
the appropriate clinical context, the diagnosis may be based on the typical morphological 
features.   
Results show that only one of 9 HHV8 LNA-1 immunostains performed in the endemic group 
was negative.  Schwartz et al (2003) investigated HHV8 LNA-1 expression in 16 cases of 
endemic KS from the 1960‟s.  Five cases (31,25%) were recorded as negative and the age 
of the tissue blocks was thought to influence the staining of these endemic cases.   
Thirteen (1,44%) cases of paediatric KS (diagnosed in patients younger than 14 years) were 
identified in this study and a median age of 7 years was demonstrated.  Of the 10 paediatric 
patients with HIV-associated KS recorded, the majority of cases (5/10) were from biopsies of 
lymph nodes and one case was of gastrointestinal origin.  Tukei et al (2011), in a study in 
which children were defined as aged between 6 weeks and 18 years, revealed a similar 
nodal predominance of KS.  In contrast, Cairncross et al (2009) reported only 1 case of 
nodal KS and 3 cases of gastrointestinal KS.  Despite being inclusive of cases of paediatric 
KS from CHBAH (in addition to cases from other South African tertiary hospitals), the 
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findings by Stefan et al (2011) contrasted those of the present study in that their median age 
was younger, the average CD4 count was higher and the most commonly affected site was 
skin.  Further studies to determine the incidence of paediatric KS may be useful in light of 
the vigorous Prevention of Mother to Child Transmission (PMTCT) antiretroviral programmes 
initiated at local clinics and CHBAH.  In data cited by Hankins (2013), new HIV infections in 
children over 2 has decreased by 24% due to the PMTCT.  The UNAIDS global report of 
2013 has estimated 21 000 new infections in children as of 2012 with a reported 234 952 
pregnant females living with HIV who received HAART for preventing mother to child 
transmission.  As such, the impact of reduced vertical transmission of HIV infection may 
result in a decline in the incidence of KS in children.  
Results of this study show that though very rare, KS in HIV negative patients (probable 
endemic KS) does present to CHBAH.  The patients regarded as having endemic KS were 
noted to have tested negative for HIV by means of HIV ELISA on one or multiple occasions 
(see table 3).  According to the South African Department of Health‟s HIV counselling and 
testing policy guidelines of 2010, confirmation of HIV infection by means of an HIV-ELISA 
test is reserved for those cases where the rapid/screening test is positive.  Pitche et al 
(2007), in a study of 20 cases of African/endemic KS, found a mean age of 49,5 years and 
M:F ratio of 9:1.  Their cases were mostly localised to the lower limbs (78,9%).  The mean 
age of patients with HIV-negative/endemic KS at CHBAH was 55,4 years with a M:F ratio of 
1,25:1.  Similarly, 50% of cases were localized to the lower limbs.  The prevalence of 
endemic KS may be under-estimated due to absence of a recorded HIV status in 161 
patients in this study.  Endemic KS, although rare in comparison to HIV associated KS, does 
still occur and as such patients who have KS should not be assumed to be HIV positive.  
Formal serological tests for confirmation/exclusion of HIV infection are warranted.  
Results of this study show that most lesions of mucocutaneous KS biopsied were of plaque 
stage, followed by nodular stage and then patch stage KS.  Patch stage KS may be a subtle 
manifestation, both clinically and histopathologically.  The subtle nature of patch stage KS 
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may account for more obvious plaque and nodular stages being biopsied for confirmation of 
KS.  Patients are more likely to recognise and be concerned about well-established and/or 
larger lesions; hence their presentation with plaque and nodular stage lesions.  From a 
clinical viewpoint, larger lesions are thought to be more representative and diagnostically 
yielding.  Therefore these lesions are targeted by the biopsying clinician.  The stages of KS 
diagnosed were not specified in 230 of the 938 histopathology reports reviewed.  Reporting 
of the histological stage is dependent on the preference of the reporting pathologist.  The 
ACTG staging for KS is not reliant on any histological parameters (Nasti et al 2003). 
The median CD4 counts calculated across the three stages of KS were similar (168 
cells/mm3 for patch stage, 129 cells/mm3 for plaque stage and 146 cells/mm3 for tumour 
stage) in this study.  The premise at the outset was that the lower the CD4 count, the greater 
the degree of immunosuppression and therefore the more advanced the KS lesion.  Patients 
with low CD4 counts were therefore assumed to present with nodular KS and those with 
higher CD4 counts with patch stage KS.  However, we have demonstrated that the CD4 
count is not predictive of the stage of KS (p = 0,701).  Patients who have HIV infection may 
have synchronous KS lesions of different stages.  The lesion biopsied and therefore the 
stage recorded by the pathologist may not produce a true reflection of the severity of the 
disease.  Clinical records regarding the number of lesions and the stages of each lesion may 
have been more useful for comparison to the CD4 count.  
This study revealed that infections represented 23,26% of the concomitant pathology 
diagnosed in KS biopsy specimens.  Herpes simplex (1 case) and possible syphilis (2 cases) 
were two concomitant infections diagnosed at CHBAH in addition to the more commonly 
described cryptococcus, cytomegalovirus and candida.  Interface dermatitis as described by 
Grayson (2011) also occurred concomitantly.  In addition, spongiotic dermatitis not otherwise 
specified and seborrheic dermatitis have also been diagnosed as concomitant pathology in 
this laboratory.  Granulomatous inflammation was seen in 7 biopsies.  PCR for 
Mycobacterium genus was positive in one case.  Ziehl neelsen special stains performed on 
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all 7 cases were negative.  Kandemir et al (2009b) reported sarcoid-like granulomas in a 
case of classic KS.  Special stains for infective causes were negative and the reaction was 
postulated to be similar to that observed in carcinomas.  Ramdial et al (2010) stressed the 
importance of adequately investigating granulomatous inflammation.  Confirmation of 
concomitant Mycobacterium tuberculosis may be crucial in diagnostic and management 
decisions by the treating clinician especially with regard to multidrug resistance and possible 
non compliance.   
One case of penile KS was confirmed at the CHBAH histopathology laboratory during the 
study period.  However, no associated squamous dysplasia or special morphologic variants 
of KS were diagnosed in this genital region.  The review article by Grayson (2011) focused 
on cases of cutaneous KS and concomitant pathology thereof.  The present study 
contributes and documents concomitant pathology occurring in the setting of extracutaneous 
KS.   
Concomitant HIV lymphadenitis/Castleman disease like features occurred in 10 of the 27 
cases of nodal KS and 1 case showed Castleman disease.  As concomitant pathology was 
noted in approximately a half of all lymph nodes biopsies, reporting pathologists should be 
vigilant.  In lymph nodes which display morphological features of KS, routine application of 
HHV8 LNA-1 immunohistochemical stains should be considered as HHV8 positive cells may 
be detected in the mantle layer of follicles thereby confirming the diagnosis of concomitant 
HHV8 associated Castleman disease.  One must be wary though of isolated circulating 
lymphocytes that may also be HHV8 positive.  Large intestinal intussusception and gastritis 
were also documented. 
Variability of HHV8 LNA-1 immunohistochemical staining was noted on review of the 
retrospective cohort of cases.  This variability was noted both in the distribution (focal vs 
diffuse) and intensity (weak vs strong) of immunohistochemical staining.  Reasons for this 
variability were explored by assessing if there was a relationship among the intensity and/or 
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the distribution of HHV8 LNA-1 immunohistochemical staining, CD4 counts of the patients at 
time of biopsy and the stages of the lesions (ie, patch, plaque or nodular). 
It was found that most biopsies in this study across all 3 stages stained strongly (102 of the 
total 127 biopsies reviewed).  No statistically significant difference was noted in the intensity 
of staining across the 3 stages of KS (p = 0,30) in this study.  When the intensity of 
combined patch and plaque stage were compared against nodular stage there was no 
statistical significance (p = 0,08).   
Most KS biopsies across all the stages stained diffusely (110 of the total 127 cases 
reviewed).  No statistically significant differences were noted as a total but when individual 
stages were compared, a statistically significant difference was noted in the distribution of 
staining between patch and nodular stage KS (p = 0,011 = <0,016).  No significant 
differences in distribution were calculated for patch vs plaque (p = 0,06) or plaque vs nodular 
stages (p = 0,21).  
A possible explanation for the variable staining was proposed by Dupin et al (1999) when 
they demonstrated immunohistochemical staining of 10-30% of cells in patch stage KS and 
attributed this limited staining in patch stage KS to the possibility that early KS is not a 
monoclonal expansion of HHV8 infected cells.  Several authors who have employed the use 
of limited KS case numbers, have attempted to address the variability of HHV8 LNA-1 
immunohistochemical staining (Hong et al 2003; Pak et al 2005; Patel et al 2004; Ramos da 
Silva et al 2007).  However, until now, there has not been a large study which has addressed 
this variability.   
The detection of focal and weak HHV8 LNA-1 immunohistochemical staining in 13% and 
20% respectively of biopsies examined at the histopathology laboratory at CHBAH, 
highlights that close scrutiny of the stained section is required.  The presence of subtle forms 
of nuclear HHV8 LNA-1 immunoreactivity can be easily overlooked resulting in an 
unnecessary repeat biopsy and delay in initiation of treatment.   
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Furthermore, the findings of this study are that the CD4 count is not predictive of the 
intensity (p = 0,878) or distribution (p = 0,846) of HHV8 LNA-1immunohistochemical staining.  
Factors other than the immune status and CD4 count may be responsible for the variability 
in HHV8 LNA-1immunohistochemical staining.  Bezold et al (2001) demonstrated that HHV8 
copy numbers (as assessed by PCR) were similar in HIV negative and HIV positive patients 
and surmised that the immune status therefore had no bearing on the HHV8 copy number.  
At present, there is no published English literature which has addressed the issue of whether 
the intensity or distribution of HHV8 LNA-1 immunohistochemical staining is reflective of 
HHV8 copy number. 
 
Limitations: 
As this was a retrospective study, patients‟ files were not available and clinical data could not 
be reviewed.  Data regarding CD4 counts in some of the cases were not available and 
additional information regarding whether patients were on HAART at the time of biopsy could 
not be retrieved.  
Automated immunohistochemical staining was introduced towards the latter half of 2009.  
Some of the HHV8 LNA-1 IHC stains reviewed were automated, the majority were manually 
stained.  In addition, controls were external rather than internal and were therefore not 
available at time of review of the stains for comparison.  However, the controls were checked 
prior to being issued to the reporting pathologist.  
Some cases fulfilling criteria for review of HHV8 LNA-1 immunostaining could not be located 
in the archives and thus had to be excluded from the study.  
There was an element of sampling bias as CHBAH is a tertiary hospital.  Patients treated at 
this hospital will have greater burden of disease (i.e. lower CD4 counts and more advanced 
HIV infection) than those treated at local clinics.  HHV8 LNA-1 immunohistochemical stains 
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showed predominantly strong and diffuse staining.  This may be a reflection of the study 
population.   
The proportion of patch, plaque and nodular stage KS for the total number available versus 
the proportion of the 3 stages in the second component of the study, ie. cases for review did 
not match.  This lack of correlation with regard to proportions was due to selection being 
limited by available CD4 counts and HHV 8 LNA-1 immunohistochemical stains.  
The criteria for defining focal (≤10%) versus diffuse staining (>10%) were arbitrarily chosen.  
It may be, that statistically significant findings may result from adjusting this cut off.  This 
aspect may form the basis of a future prospective study. 
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Chapter 6: CONCLUSION 
Kaposi sarcoma is a pathogenetically and morphologically diverse disease.  It is thought to 
be both an inflammatory and neoplastic process.  KS may present at almost any topographic 
site and may mimic other vasoformative lesions both clinically and histopathologically.  The 
epidemiology has changed dramatically since HIV associated KS was first diagnosed in the 
1980‟s.  With the introduction of HAART, the demographics may once again shift as the 
effects of therapy become apparent.   
This study highlighted the burden of KS at CHBAH and addressed the spectrum of 
histopathology that may be seen including the interesting aspects of concomitant pathology 
and variability in HHV8 LNA-1 immunohistochemical staining.   
The documentation of the features of Kaposi sarcoma and HHV-8 staining in this study 
provides a foundation on which further comparative research could be based in future.   
The demographics of KS diagnosed at CHBAH are similar to those described by others 
(Mosam et al 2008; Sitas & Newton 2000 and 2009; Tukei et al 2011).  The male:female 
ratio, mean age at presentation and CD4 counts are comparable.  
The finding of concomitant pathology in 4,6% of biopsies is of value from both clinical and 
pathologic perspectives.  Furthermore, there has been no formal previous documentation of 
concomitant pathology in extracutaneous KS. 
Paediatric, endemic and visceral KS accounted for only limited proportions of cases.  The 
typical microscopic characteristics of KS may be masked or absent in the special 
morphological variants. 
The CD4 counts of patients were not predictive of the stage of KS or the intensity and 
distribution of HHV8 LNA-1 immunohistochemical staining.  A statistically significant 
difference was noted in the distribution of staining between patch and nodular stage KS (p = 
0,011).   
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Recommendations for future research: 
 The effect of antiretroviral therapy on KS incidence at CHBAH both in adults and 
the paediatric age group. 
 Comparison of HHV8 viral load in the peripheral blood, quantity of HHV8 viral DNA 
in tissue biopsies and intensity/distribution of HHV8 LNA-1 immunohistochemical 
staining.  
 Immunohistochemical staining of cases with CD117 and cytogenetic analysis for C-
kit mutations to support treatment with Gleevec.  
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